Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

NCT04922658 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Advanced Non-Small Cell Lung Cancer

Interventions

DRUG: Surufatinib
DRUG: Surufatinib Plus Vinorelbine

Sponsor

Affiliated Cancer Hospital & Institute of Guangzhou Medical University